Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04544111
Recruitment Status : Recruiting
First Posted : September 10, 2020
Last Update Posted : May 5, 2022
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Brief Summary:
The purpose of this study is to find out whether a drug called PDR001, combined with either trametinib or dabrafenib, is a safe and effective treatment for thyroid cancer.

Condition or disease Intervention/treatment Phase
Thyroid Cancer Thyroid Cancer, Follicular Papillary Thyroid Cancer Follicular Thyroid Cancer Hurthle Cell Tumor Poorly Differentiated Thyroid Gland Carcinoma Hurthle Cell Thyroid Neoplasia Drug: Trametinib Drug: Dabrafenib Drug: PDR001 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer
Actual Study Start Date : September 2, 2020
Estimated Primary Completion Date : September 2, 2023
Estimated Study Completion Date : September 2, 2023

Arm Intervention/treatment
Experimental: Cohort A-BRAF WT tumors
Cohort A (BRAF WT tumors): trametinib (T) 2mg by mouth daily plus PDR001 400mg IV every 4 weeks
Drug: Trametinib

2mg by mouth daily

*If patient loses the ability to swallow while on study, trametinib may be provided as a powder in bottle for reconsititution. Trametinib, as a powder in bottle, will be mixed with sterile/purified water into an oral solution and administered PO or through enteral feeding tube

Drug: PDR001
400mg IV every 4 weeks

Experimental: Cohort B-BRAF Mutant
Cohort B (BRAF Mutant, resistant to previous BRAF inhibitors): dabrafenib (D) 150 mg twice daily (OR at dose the patient previously tolerated) plus PDR001 400mg IV every 4 weeks.
Drug: Dabrafenib
150 mg twice daily (OR at dose the patient previously tolerated)

Drug: PDR001
400mg IV every 4 weeks

Primary Outcome Measures :
  1. Overall response rate [ Time Frame: 1 year ]
    The primary endpoint is to determine the overall response rate (ORR=CR+PR) as documented by RECIST v1.1 criteria within each cohort.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cohort A Only: Confirmation in a CLIA certified laboratory that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastases) does not possess a BRAFV600- mutation (non-V600- BRAF mutations, including BRAF translocations, may be included in this cohort).
  • Cohort A Only: Evidence of progressive disease (e.g. presence of new or growing lesion(s) on radiologic imaging and/or new or worsening tumor-related symptoms) within 14 months of study enrollment
  • Cohort B Only: Confirmation in a CLIA certified laboratory that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastases) possesses a BRAFV600- mutation (e.g. V600E, V600K, V600D).
  • Cohort B Only: Patients must have documented progression (evidence of tumor growth or appearance of new tumor) on prior BRAF directed therapy (e.g. (but not limited to) vemurafenib, dabrafenib) and must have tolerated this therapy without > Grade 3 toxicity on their most recent evaluation (excluding Grade 4 asymptomatic laboratory abnormalities).
  • Patients must have pathologically or cytologically confirmed differentiated thyroid cancer of follicular origin (including papillary thyroid carcinoma, follicular thyroid carcinoma, hurthle cell carcinomas, poorly differentiated thyroid carcinoma and their respective variants).
  • Patients must have RECIST v1.1 measurable disease.
  • Patients must have recurrent or metastatic disease not amenable to curative surgery or radiation.
  • Age > 18 years.
  • ECOG performance status of 0 or 1.
  • Patients must have no recent treatment for thyroid cancer as defined as:

    • No prior RAI therapy is allowed <6 months prior to initiation of therapy on this protocol. A diagnostic study using <10 mCi of RAI is not considered RAI therapy
    • No external beam radiation therapy <4weeks prior to initiation of therapy on this protocol.
    • No chemotherapy or targeted therapy (e.g., tyrosine kinase inhibitor) is allowed <4 weeks prior to the initiation of therapy on this protocol (an exception to this are patients on dabrafenib who will be enrolling into Cohort B). Dabrafenib may be continued prior to and through trial enrollment into the start of the study therapy when PDR001 will be added to dabrafenib
  • RAI-refractory disease on structural imaging, defined as one of the following:

    • Total lifetime dose of radioiodine > 600 mCi
    • A tumor that is not radioiodine-avid on a diagnostic radioiodine scan performed prior to enrollment in the current study.
    • A radioiodine-avid metastatic lesion which remained stable in size or progressed despite radioiodine treatment 6 months or more prior to study entry in the study. There are no size limitations for the index lesions used to satisfy this entry criterion
    • The presence of at least one fluorodeoxyglucose (FDG) avid lesion.
  • Patients must be able to swallow and retain orally-administered pills without any clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome or major resection of the stomach or bowels.
  • Patients must have tissue from the primary tumor or metastases available for correlative studies. Either a paraffin block or at least 20 unstained slides are acceptable (30 unstained slides would be ideal). (If less than twenty unstained slides are available and a paraffin bloc is not available, the patient may be able to participate at the discretion of the investigator).
  • Patients must agree to undergo two research biopsies of (a) malignant lesion(s). Tumor tissue obtained prior to study consent or treatment as part of standard of care can also be submitted in lieu of performance of the first pre-treatment biopsy if the Principal Investigator deems it to be of sufficient quantity/quality/timeliness. Patients may be exempt from biopsy if 1) the investigator or person performing the biopsy judges that no tumor is accessible for biopsy, 2) the investigator or person performing the biopsy feels that the biopsy poses too great of a risk to the patient, or 3) the patient cannot be safely removed from anti-coagulation therapy (if the anti-coagulation therapy needs to be temporarily held for the biopsy procedure). If the only tumor accessible for biopsy is also the only lesion that can be used for RECIST v1.1 response evaluation, then the patient may be exempt from biopsy. If the investigator deems a second research biopsy to be high risk after a patient has completed the first research biopsy, the patient may be exempt from the second biopsy.
  • Screening laboratory values must meet the following criteria:

    • WBC ≥ 2000/µl
    • Neutrophils ≥ 1500/µl
    • Platelets ≥ 100 x 10^3/µl
    • Hemoglobin > 9.0 g/dL
    • AST/ALT ≤ 3 x ULN
    • Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
    • Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (if using the Cockcroft-Gault formula below):

Female CrCl = (140 - age in years) x weight in kg x 0.85/72 x serum creatinine in mg/dL

Male CrCl = (140 - age in years) x weight in kg x 1.00/72 x serum creatinine in mg/dL

  • Left ventricular ejection fraction ≥ institutional lower limit of normal by transthoracic echocardiogram (ECHO) performed within 1 month of study drug initiation.

Exclusion Criteria:

  • Cohort A Only:

    • Patients with the following ophthalmological finding/conditions:
  • Intraocular pressure >21 mmHg, or uncontrolled glaucoma (irrespective of intraocular pressure).
  • Current or past history of central serous retinopathy or retinal vein occlusion.
  • Cohort A Only: Prior therapy with a MEK 1/2 targeted drug (with the exception of patients who received this therapy for a defined period of time to enhance radioiodine activity).
  • Symptomatic metastatic brain or leptomeningeal tumors (asymptomatic or treated metastatic brain or leptomeningeal tumors are allowed).
  • Prior therapy directed at the PD1/PD-L1 axis.
  • Any of the following cardiovascular risks:

    • A QT interval corrected for heart rate using the Bazett's formula QTcB ≥ 480 msec.
    • Clinically significant uncontrolled arrhythmias (Exception: patients with controlled atrial fibrillation for >30 days prior to enrollment are eligible).
    • Acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months of enrollment.
    • ≥ Class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system.
    • Treatment-refractory hypertension defined as a blood pressure of systolic >140 mmHg and/or diastolic >90 mmHg which cannot be controlled by anti-hypertensive therapy.
  • Prior malignancy if treated within 2 years of trial drug initiation (with the exception of non-melanoma skin cancers). Patients may be included if they have completed therapy for a prior malignancy >2 years prior to drug initiation and are currently NED.
  • Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment.
  • Systemic chronic steroid therapy (≥ 10mg/day prednisone or equivalent) or any immunosuppressive therapy (including but not limited to methotrexate, azathioprine, and TNF-alpha blockers) 7 days prior to planned first date of study treatment (note: topical, inhaled, nasal, intra-articular and ophthalmic steroids are allowed).
  • Active, known or suspected autoimmune disease or documented history of autoimmune disease with the exception of vitiligo, controlled type I diabetes mellitus on stable insulin, autoimmune thyroid disease or psoriasis not requiring systemic treatment.
  • Allogenic bone marrow or solid organ transplant.
  • History of severe hypersensitivity reactions to monoclonal antibodies or any other study drug components which in the opinion of the investigator may pose an increased risk of serious infusion reaction.
  • Known history of current interstitial lung disease or non-infectious pneumonitis.
  • Patients with active hepatitis B infection (HBV surface antigen positive).
  • Subject is known to be positive for Human Immunodeficiency Virus (HIV) or active Hepatitis C Virus (HCV). Testing for HIV or Hepatitis C prior to initiation of the study drug is not required. If a patient has a known history of treated HCV, then a viral load is required to confirm clearance of infection.
  • Pregnant or nursing (lactating) women confirmed by a positive hCG laboratory test within 72 hours prior to initiating study treatment.
  • Women of child-bearing potential (as defined in Appendix 18.3), unless they are using highly effective methods of contraception during dosing and for 150-days after stopping treatment with PDR001. Highly effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
    • Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that patient
    • Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception. NOTE: In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
    • Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
  • Sexually active males unless they use a condom during intercourse while on treatment and for 150 days after stopping treatment with PDR001 and should not father a child in this period. A condom is required to be used by vasectomized men as well during intercourse to prevent delivery of the drug via semen.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04544111

Layout table for location contacts
Contact: Alan L Ho, MD, PhD 646-608-3774
Contact: David G Pfister, MD 646-888-4237

Layout table for location information
United States, New Jersey
Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities) Recruiting
Basking Ridge, New Jersey, United States, 07920
Contact: Alan Ho, MD. PhD    646-608-3774      
Memoral Sloan Kettering Monmouth (Limited protocol activities) Recruiting
Middletown, New Jersey, United States, 07748
Contact: Alan Ho, MD, PhD    646-608-3774      
Memorial Sloan Kettering Bergen (Limited Protocol Activities) Recruiting
Montvale, New Jersey, United States, 07645
Contact: Alan Ho, MD, PhD    646-608-3774      
United States, New York
Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities) Recruiting
Commack, New York, United States, 11725
Contact: Alan Ho, MD, PhD    646-608-3774      
Memoral Sloan Kettering Westchester (Limited protocol activities) Recruiting
Harrison, New York, United States, 10604
Contact: Alan Ho, MD, PhD    646-608-3774      
Memorial Sloan Kettering Cancer Center (All Protocol Activities) Recruiting
New York, New York, United States, 10065
Contact: Alan Ho, MD. PhD    646-608-3774      
Contact: David Pfister, MD    646-888-4237      
Memorial Sloan Kettering Nassau (Limited protocol activities) Recruiting
Rockville Centre, New York, United States, 11553
Contact: Alan Ho, MD, PhD    646-608-3774      
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Layout table for investigator information
Principal Investigator: Alan L Ho, MD, PhD Memorial Sloan Kettering Cancer Center
Additional Information:
Layout table for additonal information
Responsible Party: Memorial Sloan Kettering Cancer Center Identifier: NCT04544111    
Other Study ID Numbers: 20-258
First Posted: September 10, 2020    Key Record Dates
Last Update Posted: May 5, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to:

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Memorial Sloan Kettering Cancer Center:
Thyroid Cancer
Radioiodine-Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Additional relevant MeSH terms:
Layout table for MeSH terms
Thyroid Neoplasms
Thyroid Cancer, Papillary
Adenocarcinoma, Follicular
Adenoma, Oxyphilic
Thyroid Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Adenocarcinoma, Papillary
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immune Checkpoint Inhibitors